Employers › Tercica
Recordkeeping fees per participant · Ipsen Biopharmaceuticals, Inc. U.S. 401(k) Plan · plan year 2024
$55.03
Higher than 39% of the 5,847 plans $50 to 250M that report it.
= $65,648 / 1,193
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250929145255NAL0010997649001, received 2025-09-29
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250929145255NAL0010997649001, received 2025-09-29
Percentiles compare this plan with the Schedule H plans $50 to 250M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-09-29.
Administrative expenses excluding investment management, per participant
$78.71
Higher than 41% of the 8,758 plans $50 to 250M that report it.
= $93,898 / 1,193
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250929145255NAL0010997649001, received 2025-09-29
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250929145255NAL0010997649001, received 2025-09-29
Administrative expenses per participant
$78.71
Higher than 27% of the 9,042 plans $50 to 250M that report it.
= $93,898 / 1,193
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250929145255NAL0010997649001, received 2025-09-29
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250929145255NAL0010997649001, received 2025-09-29
Administrative expenses as a share of assets
0.046%
Higher than 18% of the 9,049 plans $50 to 250M that report it.
= $93,898 / $205,813,547
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250929145255NAL0010997649001, received 2025-09-29
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250929145255NAL0010997649001, received 2025-09-29
Employer contributions per participant
$13,401
Higher than 97% of the 9,105 plans $50 to 250M that report it.
= $15,987,988 / 1,193
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250929145255NAL0010997649001, received 2025-09-29
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250929145255NAL0010997649001, received 2025-09-29
Employer share of total contributions
44.2%
Higher than 83% of the 9,112 plans $50 to 250M that report it.
= $15,987,988 / $36,181,788
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250929145255NAL0010997649001, received 2025-09-29
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250929145255NAL0010997649001, received 2025-09-29
Plan terms are described in Tercica Inc's SEC filings: Form 10-K filed 2008-02-29. No term could be quoted from them with the required precision.
2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2T default investment (QDIA) · 2E profit-sharing · 3F · 3H controlled-group sponsor · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20250929145255NAL0010997649001, received 2025-09-29
| Field | Value | Source |
|---|---|---|
| Plan sponsor | IPSEN BIOPHARMACEUTICALS, INC | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Plan name | IPSEN BIOPHARMACEUTICALS, INC. U.S. 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Sponsor EIN / plan number | 26-0042539 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Sponsor location | BERKELEY HEIGHTS, NJ | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Industry (business code) | 424210, Wholesale trade | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Filing received | 2025-09-29 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Participants, beginning of year | 1,211 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Active participants | 683 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Participants, end of year | 1,219 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Participants with an account balance | 1,193 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total assets, beginning of year | $165,883,134 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total assets, end of year | $205,813,547 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Net assets, end of year | $205,813,547 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total income | $62,463,577 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Net income | $39,930,413 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Employer contributions | $15,987,988 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Participant contributions | $13,882,284 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Other contributions (incl. rollovers) | $6,311,516 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total contributions | $36,181,788 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Benefit payments | $22,416,715 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total expenses (incl. benefit payments) | $22,533,164 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Total administrative expenses | $93,898 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Recordkeeping fees | $65,648 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| IQPA audit fees | $28,250 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Investment advisory and management fees | $0 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Administrative expenses excluding investment management | $93,898 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Held in common/collective trusts | $5,157,169 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Held in mutual funds | $199,510,453 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20250929145255NAL0010997649001, received 2025-09-29 |
| Independent auditor | BAKER TILLY US, LLP | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20250929145255NAL0010997649001, received 2025-09-29 |
Position = column in the DOL layout for form year 2024. Filing 20250929145255NAL0010997649001, received 2025-09-29.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 60 Sub-transfer agency fees; 64 Recordkeeping fees; 65 Account maintenance fees | $65,648 | yes |
| MOSS ADAMS LLP | ACCOUNTANT/AUDITOR | 10 Accounting (including auditing) | $28,250 | no |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20250929145255NAL0010997649001, received 2025-09-29.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $165,883,134 | $205,813,547 | 24.1% |
| Participants with a balance | 1,181 | 1,193 | 1.0% |
| Administrative expenses | $92,432 | $93,898 | 1.6% |
| Recordkeeping fees per participant | $77.25 | $55.03 | -28.8% |
| Employer contributions | $14,494,898 | $15,987,988 | 10.3% |
Prior filing 20241004123137NAL0005694467001, received 2024-10-04; the plan years are contiguous.
Sponsor name as filed: IPSEN BIOPHARMACEUTICALS, INC; SEC registrant: TERCICA INC (CIK 1262175, matched by EIN).